GlassScriptPhysician profile
Jason L Ignatius
NPI 1447485263
$202,326.91
in general payments reported to CMS, 2019-2025
51 companies · $3,961 in 2025
The $3,961 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $42K · 2021: $59K · 2022: $30K · 2023: $9,091 · 2024: $3,954 · 2025: $3,961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,201 · Education: $418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,386.56 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,201.33 |
| Education | $418.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $70,353.73 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $48,499.18 | 2019-2025 | |
| Amgen INC. | $31,266.53 | 2019-2025 | Aimovig, Uplizna |
| Allergan, INC. | $20,152.85 | 2019-2021 | |
| Lilly USA, LLC | $9,326.28 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Biohaven Pharmaceuticals, INC. | $6,584.95 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $3,818.57 | 2022 | |
| Biogen, INC. | $1,784.54 | 2019-2025 | Vumerity, Tysabri, Spinraza |
| Ucb, INC. | $1,120.14 | 2019-2025 | Briviact, Nayzilam |
| Lundbeck LLC | $832.86 | 2019-2025 | Vyepti, Rexulti |
| Genentech USA, INC. | $829.72 | 2021-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Mdd US Operations, LLC | $671.40 | 2019-2025 | Gocovri, Gocovri |
| Pfizer INC. | $562.44 | 2023-2025 | |
| Celgene Corporation | $528.66 | 2020-2025 | Zeposia |
| Alexion Pharmaceuticals, INC. | $496.36 | 2021-2023 | Ultomiris |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Ignatius listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.